Can Baseline [<sup>18</sup>F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Can Baseline [¹⁸F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study

Published:2023-05-01 Issue:4 Volume:38 Page:256-267
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Bianchi Andrea¹,De Rimini Maria Luisa²,Sciuto Rosa³,Annovazzi Alessio³,Di Traglia Silvia³,Bauckneht Matteo⁴⁵,Lanfranchi Francesco⁴⁵,Morbelli Silvia⁴⁵,Nappi Anna Giulia⁶,Ferrari Cristina⁶,Rubini Giuseppe⁶,Panareo Stefano⁷,Urso Luca⁸,Bartolomei Mirco⁸,D'Arienzo Davide²,Valente Tullio⁹,Rossetti Virginia¹⁰,Caroli Paola¹⁰,Matteucci Federica¹⁰,Aricò Demetrio¹¹,Bombaci Michelangelo¹¹,Caponnetto Domenica¹¹,Bertagna Francesco¹²,Albano Domenico¹²,Dondi Francesco¹²,Gusella Sara¹³,Spimpolo Alessandro¹³,Carriere Cinzia¹⁴,Balma Michele¹,Buschiazzo Ambra¹,Gallicchio Rosj¹⁵,Storto Giovanni¹⁵,Ruffini Livia¹⁶,Scarlattei Maura¹⁶,Baldari Giorgio¹⁶,Cervino Anna Rita¹⁷,Cuppari Lea¹⁷,Burei Marta¹⁷,Trifirò Giuseppe¹⁸,Brugola Elisabetta¹⁸,Zanini Carolina Arianna¹⁹,Alessi Alessandra²⁰,Fuoco Valentina²⁰,Seregni Ettore²⁰,Deandreis Désirée²¹,Liberini Virginia¹²¹,Moreci Antonino Maria²²,Ialuna Salvatore²²,Pulizzi Sabina²²,Evangelista Laura²³

Affiliation:

1. Nuclear Medicine Unit, SC Medicina Nucleare, ASO S.Croce e Carle Cuneo, Cuneo, Italy.

2. Nuclear Medicine Unit, Department of Health Service, AORN Ospedali dei Colli, Naples, Italy.

3. Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

4. Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.

5. Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

6. Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro,” Bari, Italy.

7. Nuclear Medicine Unit, Oncology and Haematology Department, University Hospital of Modena, Modena, Italy.

8. Nuclear Medicine Unit, Oncology and Specialistic Department, University Hospital of Ferrara, Ferrara, Italy.

9. U.O.C. Radiologia, Department of Servizi, AORN Ospedali dei Colli, Napoli, Italy.

10. Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy.

11. Servizio di Medicina Nucleare, Humanitas Istituto Clinico Catanese, Misterbianco, Italy.

12. Nuclear Medicine Unit, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy.

13. Nuclear Medicine Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.

14. Dermatology Department, Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Italy.

15. Nuclear Medicine Unit, IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.

16. Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy.

17. Nuclear Medicine Unit, Veneto Institute of Oncology IOV—IRCSS, Padua, Italy.

18. Servizio di Medicina Nucleare ICS MAUGERI SPA SB—IRCCS, Pavia, Italy.

19. Department of Nuclear Medicine, Università Degli Studi di Milano, Milano Statale, Milan, Italy.

20. Nuclear Medicine Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

21. Nuclear Medicine Division, Department of Medical Sciences, University of Turin, Turin, Italy.

22. Nuclear Medicine Unit, Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, Palermo, Italy.

23. Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2022.0092

Reference19 articles.

1. Metastatic melanoma treatment: Combining old and new therapies

2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

3. Nivolumab in melanoma: latest evidence and clinical potential

4. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma